Here you can find the latest TOPADUR news & events.
Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.
The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds.
EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.
TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.
Do you need more information or references? Media contact